

Jeffrey A Lieberman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3304977/publications.pdf>

Version: 2024-02-01

195
papers

11,251
citations

270111

25
h-index

175968

55
g-index

340
all docs

340
docs citations

340
times ranked

12858
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin, 2022, 48, 199-210.	2.3	11
2	Hippocampal Glutamate and Positive Symptom Severity in Clinical High Risk for Psychosis. JAMA Psychiatry, 2022, 79, 178.	6.0	3
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
4	Neurodegenerative model of schizophrenia: Growing evidence to support a revisit. Schizophrenia Research, 2022, 243, 154-162.	1.1	36
5	Anti-viral properties of antipsychotic medications in the time of COVID-19. Psychiatry Research, 2021, 295, 113626.	1.7	7
6	Psychotic symptoms in mass shootings v. mass murders not involving firearms: findings from the Columbia mass murder database. Psychological Medicine, 2021, , 1-9.	2.7	15
7	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. Translational Psychiatry, 2021, 11, 419.	2.4	45
8	The neurobiology of auditory and visual perceptual abnormalities in a clinical high-risk for psychosis cohort: A pilot morphometric magnetic resonance imaging study. Journal of Psychiatric Research, 2021, 142, 240-242.	1.5	1
9	High-impact rare genetic variants in severe schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	29
10	Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia. Biological Psychiatry, 2020, 87, 234-242.	0.7	61
11	An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS. Schizophrenia Research, 2020, 226, 70-73.	1.1	9
12	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research: Cognition, 2020, 19, 100161.	0.7	2
13	How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry, the, 2020, 7, 813-824.	3.7	1,101
14	Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China. JAMA Psychiatry, 2020, 77, 1116.	6.0	27
15	Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study. Schizophrenia Research, 2020, 218, 321-323.	1.1	2
16	Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology. Schizophrenia Research, 2020, 220, 1-15.	1.1	6
17	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109952.	2.5	8
18	A predictive model for conversion to psychosis in clinical high-risk patients. Psychological Medicine, 2019, 49, 1128-1137.	2.7	34

#	ARTICLE	IF	CITATIONS
19	Richard Resnick. <i>Neuropsychopharmacology</i> , 2019, 44, 1674-1674.	2.8	0
20	Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. <i>American Journal of Psychiatry</i> , 2019, 176, 794-810.	4.0	100
21	Amygdalar volume and violent ideation in a sample at clinical high-risk for psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2019, 287, 60-62.	0.9	6
22	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. <i>NeuroImage: Clinical</i> , 2019, 22, 101739.	1.4	27
23	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. <i>Pharmacogenomics Journal</i> , 2019, 19, 211-218.	0.9	25
24	Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. <i>Journal of Psychopharmacology</i> , 2018, 32, 533-540.	2.0	19
25	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2018, 19, S97-S105.	1.3	11
26	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 1317-1323.	2.8	80
27	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. <i>JAMA Psychiatry</i> , 2018, 75, 11.	6.0	88
28	Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective. <i>World Psychiatry</i> , 2018, 17, 163-165.	4.8	4
29	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	1.2	61
30	Raising the standard of care for schizophrenia is an achievable goal. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 637-638.	1.3	0
31	Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population. <i>JAMA Psychiatry</i> , 2017, 74, 104.	6.0	24
32	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.	9.4	838
33	A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 428-435.	2.0	49
34	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , 2016, 2, 185-197.	3.0	14
35	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016, 31, 121-134.	0.7	19
36	A Scientific Pioneer of Psychiatry. <i>American Journal of Psychiatry</i> , 2016, 173, 574-574.	4.0	0

#	ARTICLE	IF	CITATIONS
37	Brain Regions Associated With Internalizing and Externalizing Psychiatric Symptoms in Patients With Penetrating Traumatic Brain Injury. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 104-111.	0.9	6
38	Mechanisms of Working Memory Impairment in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 80, 617-626.	0.7	96
39	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 221-229.	1.3	24
40	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processingâ€“Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 799-806.	1.1	22
41	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1353-e1353.	1.1	0
42	General Approaches to Substance Use Disorders. , 2015, , 1394-1400.		0
43	Physician-Patient Relationship. , 2015, , 20-33.		0
44	Professional Ethics and Boundaries. , 2015, , 71-84.		0
45	Legal Issues in Psychiatric Practice. , 2015, , 85-98.		0
46	Psychiatric Classification. , 2015, , 655-671.		0
47	Pharmacologic Treatment of Insomnia. , 2015, , 2193-2204.		0
48	Clinical Evaluation and Treatment Planning: A Multimodal Approach. , 2015, , 499-522.		2
49	Alterations of Speech, Thought, Perception, and Self-Experience. , 2015, , 536-546.		0
50	Trauma- and Stressor-Related Disorders: Reactive Attachment Disorder and Disinhibited Social Engagement Disorder. , 2015, , 1170-1177.		0
51	Management of Agitation. , 2015, , 2479-2486.		1
52	Pharmacological Management of Treatment-Resistant Unipolar Depression. , 2015, , 2311-2330.		1
53	Child and Adolescent Psychiatric Consultation. , 2015, , 2423-2426.		0
54	Restraint and Seclusion. , 2015, , 2487-2491.		0

#	ARTICLE	IF	CITATIONS
55	Correctional Psychiatry. , 2015, , 2564-2573.		0
56	Sexual Dysfunctions. , 2015, , 1311-1338.		1
57	Gambling Disorder. , 2015, , 1638-1646.		0
58	Group Psychotherapy. , 2015, , 1923-1942.		2
59	Neurodevelopmental Disorders: Motor Disorders. , 2015, , 779-790.		1
60	Somatic Symptom and Related Disorders: Factitious Disorders. , 2015, , 1222-1230.		0
61	Early Psychosis Intervention Services: A Work in Progress. Schizophrenia Bulletin, 2015, 41, 23-24.	2.3	6
62	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. JAMA Psychiatry, 2015, 72, 316.	6.0	304
63	Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatric Services, 2015, 66, 691-698.	1.1	140
64	Response to Kornfeld. American Journal of Psychiatry, 2015, 172, 911-911.	4.0	0
65	Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO. Schizophrenia Research, 2015, 168, 373-376.	1.1	22
66	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1347-1354.	2.8	26
67	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	5.8	153
68	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. Schizophrenia Research, 2014, 152, 325-332.	1.1	144
69	Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends in Endocrinology and Metabolism, 2014, 25, 593-600.	3.1	95
70	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research, 2014, 219, 255-260.	1.7	13
71	Early Detection and Intervention in Schizophrenia. JAMA - Journal of the American Medical Association, 2013, 310, 689.	3.8	54
72	A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. Neuropsychopharmacology, 2009, 34, 1322-1329.	2.8	155

#	ARTICLE	IF	CITATIONS
73	Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. <i>Pharmacological Reviews</i> , 2008, 60, 358-403.	7.1	213
74	Brain Stimulation in Psychiatry. , 2008, , 2354-2371.		6
75	Science and Recovery in Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 487-496.	1.1	133
76	Sleep and Sleep-Wake Disorders. , 2008, , 1626-1657.		1
77	A Brief History of Psychiatry. , 2008, , 203-242.		5
78	Genetic Epidemiology and Molecular Genetics of Psychiatric Disorders. , 2008, , 257-274.		0
79	Childhood Disorders: Feeding and Related Disorders of Infancy or Early Childhood. , 2008, , 830-846.		9
80	Medication-Induced Movement Disorders. , 2008, , 1773-1793.		4
81	Pathophysiology of Addiction. , 2008, , 354-378.		5
82	Neuroprotection: A New Strategy in the Treatment of Schizophrenia. <i>CNS Spectrums</i> , 2007, 12, 1-16.	0.7	24
83	The impossible dream: can psychiatry prevent psychosis?. <i>Microbial Biotechnology</i> , 2007, 1, 219-221.	0.9	6
84	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e04.	1.1	144
85	Comparative Effectiveness of Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 2006, 63, 1069.	13.8	85
86	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1209-1223.	13.9	5,335
87	Antipsychotic Drugs. , 0, , 2161-2201.		18
88	Pharmacologic Treatment of Insomnia. , 0, , 2254-2263.		1
89	Patient Compliance. , 0, , 2447-2461.		2
90	Managing Psychological Consequences in Disaster Populations. , 0, , 2465-2477.		1

#	ARTICLE	IF	CITATIONS
91	Management of the Patient in Geriatric Psychiatry. , 0, , 2549-2562.		2
92	Management of Victims of Torture. , 0, , 2563-2575.		1
93	Treatment of Violent Behavior. , 0, , 2602-2615.		5
94	Are there Biological Commonalities among Different Psychiatric Disorders?. , 0, , 243-256.		3
95	Modeling Psychiatric Disorders in Experimental Animals. , 0, , 275-288.		2
96	The Neurobiology of Schizophrenia. , 0, , 301-316.		11
97	Neuroscience of Autism. , 0, , 379-392.		2
98	Psychopathology Across the Life Span. , 0, , 487-524.		3
99	Neuropsychological Assessment and Neurophysiological Evaluation. , 0, , 556-569.		2
100	Culture and Psychiatric Diagnosis. , 0, , 648-658.		6
101	The Cultural Context of Clinical Assessment. , 0, , 54-66.		13
102	Childhood Disorders: Intellectual Disability. , 0, , 689-746.		5
103	Childhood Disorders: Learning and Motor Skills Disorders. , 0, , 747-764.		2
104	Childhood Disorders: Attention-Deficit and Disruptive Behavior Disorders. , 0, , 804-829.		3
105	Mental Disorders Due to a General Medical Condition. , 0, , 931-956.		1
106	Substance Abuse: Caffeine Use Disorders. , 0, , 1019-1040.		7
107	Substance Abuse: Hallucinogen- and MDMA-Related Disorders. , 0, , 1100-1126.		3
108	Substance Abuse: Inhalant-Related Disorders. , 0, , 1127-1148.		7

#	ARTICLE	IF	CITATIONS
109	Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. , 0, , 1186-1200.		4
110	Mood Disorders: Depression. , 0, , 1283-1331.		4
111	Mood Disorders: Bipolar (Manic-Depressive) Disorders. , 0, , 1333-1378.		2
112	Mood Disorders: Premenstrual Dysphoric Disorder. , 0, , 1379-1391.		2
113	Anxiety Disorders: Panic Disorder With and Without Agoraphobia. , 0, , 1392-1408.		1
114	Anxiety Disorders: Obsessive-Compulsive Disorder. , 0, , 1443-1471.		1
115	Dissociative Disorders. , 0, , 1558-1577.		2
116	Infant Development: The First 3 Years of Life. , 0, , 109-134.		1
117	Relational Problem Related to a Mental Disorder or General Medical Condition. , 0, , 1794-1814.		1
118	Individual Psychoanalytic Psychotherapy. , 0, , 1851-1874.		4
119	Brief Psychotherapies. , 0, , 1889-1903.		2
120	Group Psychotherapy. , 0, , 1904-1919.		4
121	Cognitive and Behavioral Therapies. , 0, , 1920-1947.		3
122	Psychosocial Rehabilitation. , 0, , 2047-2058.		2
123	Psychiatric Rehabilitation for Achieving Successful Community Living for Adults with Psychiatric Disabilities. , 0, , 2059-2082.		3
124	Advocacy, Self-Help, and Consumer- Operated Services. , 0, , 2083-2096.		2
125	Psychological Factors Affecting Medical Condition. , 0, , 1754-1772.		0
126	Substance Abuse: Nicotine Dependence. , 0, , 1149-1168.		0

#	ARTICLE	IF	CITATIONS
127	Organization and Economics of Mental Health Treatment. , 0, , 1817-1848.		0
128	Couples Therapy. , 0, , 1963-1981.		0
129	Psychopharmacology: Ethnic and Cultural Perspectives. , 0, , 2112-2122.		1
130	Restraints and Seclusion. , 0, , 2491-2495.		0
131	Pharmacological Treatment of Substance Abuse Disorders. , 0, , 2390-2416.		1
132	Factitious Disorders. , 0, , 1548-1557.		0
133	Anxiety Disorders: Social and Specific Phobias. , 0, , 1409-1442.		2
134	Substance Abuse: Phencyclidine Use Disorders. , 0, , 1090-1099.		0
135	Substance Abuse: Cannabis-Related Disorders. , 0, , 1041-1057.		0
136	Dementia, Delirium, and Other Cognitive Disorders. , 0, , 897-930.		0
137	School-Age Development. , 0, , 150-160.		2
138	Mood Stabilizers. , 0, , 2202-2222.		0
139	Adjustment Disorders. , 0, , 1702-1717.		0
140	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 0, , 2294-2317.		0
141	A Psychiatric Perspective on Human Development. , 0, , 95-108.		0
142	Stimulants. , 0, , 2264-2293.		1
143	Physical Signs and Symptoms. , 0, , 621-632.		1
144	Childhood Disorders: The Pervasive Developmental Disorders. , 0, , 779-803.		0

#	ARTICLE	IF	CITATIONS
145	Anxiety Disorders: Traumatic Stress Disorders. , 0, , 1472-1493.		0
146	Legal Issues in Psychiatric Practice. , 0, , 81-94.		0
147	Listening to the Patient. , 0, , 1-19.		3
148	Psychiatric Conditions in Women during Reproductive Transitions. , 0, , 2507-2515.		0
149	Gender Identity and Sexual Orientation. , 0, , 2538-2548.		3
150	Psychiatric Classification. , 0, , 659-678.		0
151	Neurodegeneration and Dementia. , 0, , 393-400.		0
152	Neurobiologic Foundations of Mood Disorders. , 0, , 339-353.		0
153	Serving People Who Have Mental Illness and Homelessness. , 0, , 2526-2537.		0
154	Substance Abuse: Opioid Use Disorders. , 0, , 1169-1185.		0
155	Death and Bereavement. , 0, , 2516-2525.		0
156	Pharmacologic Management of Treatment-Resistant Unipolar Depression. , 0, , 2372-2389.		0
157	Behavioral Medicine. , 0, , 2027-2046.		1
158	Management of the Suicidal Patient. , 0, , 2478-2490.		1
159	Sexual Disorders. , 0, , 1578-1608.		0
160	Preschool Development. , 0, , 135-149.		0
161	Psychiatric Epidemiology. , 0, , 401-432.		0
162	Psychoanalytic Theories. , 0, , 464-485.		0

#	ARTICLE	IF	CITATIONS
163	Childhood Disorders: Tic Disorders. , 0 , 847-867.		0
164	Clinical Evaluation and Treatment Planning: A Multimodal Approach. , 0 , 525-545.		1
165	Consciousness, Orientation, and Memory. , 0 , 582-594.		0
166	Anxiety Disorders: Generalized Anxiety Disorder. , 0 , 1494-1509.		0
167	The Psychiatric Interview: Settings and Techniques. , 0 , 33-53.		0
168	Physician-Patient Relationship. , 0 , 20-32.		1
169	Research Methodology and Statistics. , 0 , 2619-2634.		6
170	Complementary and Alternative Treatments in Psychiatry. , 0 , 2318-2353.		1
171	Combined Treatment with Medications and Psychotherapy. , 0 , 2430-2446.		1
172	Impulse-Control Disorders. , 0 , 1658-1701.		0
173	Behavior and Adaptive Functioning. , 0 , 633-647.		0
174	Late Life. , 0 , 196-202.		2
175	Stereotyped Movement Disorder and Reactive Attachment Disorder. , 0 , 889-896.		0
176	Childhood Disorders: Communication Disorders. , 0 , 765-778.		0
177	Substance Abuse: Amphetamine Use Disorders. , 0 , 1005-1018.		0
178	Childhood Disorders: Elimination Disorders and Childhood Anxiety Disorders. , 0 , 868-888.		1
179	Correctional Psychiatry. , 0 , 2593-2601.		0
180	Interpersonal Psychotherapy. , 0 , 1875-1888.		0

#	ARTICLE	IF	CITATIONS
181	Professional Ethics and Boundaries. , 0 , 67-80.		0
182	Schizophrenia and Other Psychoses. , 0 , 1201-1282.		6
183	Pharmacologic Issues During Pregnancy. , 0 , 2417-2429.		0
184	Anxiolytic Drugs. , 0 , 2223-2253.		0
185	Psychiatric Management of Victims of Physical and Sexual Abuse and Rape. , 0 , 2576-2592.		0
186	Cognitive Psychology. , 0 , 433-453.		0
187	Adolescent Development. , 0 , 161-180.		3
188	The Scientific Basis of Psychotherapy. , 0 , 289-300.		0
189	General Approaches to Substance and Polydrug Use Disorders. , 0 , 957-970.		2
190	Brain Imaging in Psychiatry. , 0 , 570-581.		0
191	Substance Abuse: Alcohol Use Disorders. , 0 , 971-1004.		0
192	The Initial Psychiatric Evaluation of Children and Adolescents. , 0 , 546-555.		0
193	Diagnostic Classification in Infancy and Early Childhood. , 0 , 679-688.		2
194	Adult Development. , 0 , 181-195.		3
195	Substance Abuse: Cocaine Use Disorders. , 0 , 1058-1089.		0